Elafibranor:A promising treatment for alcoholic liver disease,metabolic-associated fatty liver disease,and cholestatic liver disease  

作　　者：Hang Zhang Xuan Dong Lei Zhu Fu-Shan Tang 

机构地区：[1]Department of Clinical Pharmacy,Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [2]Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education,Zunyi Medical University,Zunyi 563006,Guizhou Province,China [3]Key Laboratory of Clinical Pharmacy in Zunyi City,Zunyi Medical University,Zunyi 563006,Guizhou Province,China

出　　处：《World Journal of Gastroenterology》2024年第40期4393-4398,共6页世界胃肠病学杂志（英文）

摘　　要：Liver diseases pose a significant threat to human health.Although effective therapeutic agents exist for some liver diseases,there remains a critical need for advancements in research to address the gaps in treatment options and improve patient outcomes.This article reviews the assessment of Elafibranor's effects on liver fibrosis and intestinal barrier function in a mouse model of alcoholic liver disease(ALD),as reported by Koizumi et al in the World Journal of Gastroenterology.We summarize the impact and mechanisms of Elafibranor on ALD,metabolic-associated fatty liver disease,and cholestatic liver disease based on current research.We also explore its potential as a dual agonist of PPARα/δ,which is undergoing Phase III clinical trials for metabolic-associated steatohepatitis.Our goal is to stimulate further investigation into Elafibranor's use for preventing and treating these liver diseases and to provide insights for its clinical application.

关 键 词：Elafibranor Peroxisome proliferator activated receptor Liver fibrosis Alcoholic liver disease Metabolic-associated fatty liver disease Metabolic-associated steatohepatitis Cholestatic liver disease Primary biliary cholangitis Liver diseases 

分 类 号：R575.5[医药卫生—消化系统]